Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029704 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT01029704 is a Phase 2 study that has completed, run by Theracos. The registered enrollment target is 151 participants.
The verdict
NCT01029704, a Phase 2 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes. The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT0001442 has on the amount of glucose produced in the body by the urine.
Interventions
- DRUG EGT0001442
- DRUG Placebo capsules to match EGT0001442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01029704
The ClinicalTrials.gov registry entry for NCT01029704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EGT0001442 is the first listed.
NCT01029704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01029704 about?
NCT01029704 is a clinical study titled "Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes. The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT000144...
What is the current status of trial NCT01029704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2009-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01029704?
The interventions under investigation include: EGT0001442 (DRUG), Placebo capsules to match EGT0001442 (DRUG).
Who is sponsoring clinical trial NCT01029704?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.